Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL164600 | 0.97 | PARP1 (0.42) | PARP1GAAMAPT | |
| Water SCHEMBL15092682 | 0.94 | PARP1 (0.41) | PARP1GAAMAPT | |
| Hydrochloric Acid SCHEMBL163943 | 0.94 | PARP1 (0.46) | PARP1GAAMAPT | |
| Hydrochloric Acid SCHEMBL166212 | 0.91 | PARP1 (0.44) | PARP1GAAMAPT | |
| Methyl Alcohol SCHEMBL15757621 | 0.88 | PARP1 (0.38) | PARP1GAAMAPT | |
| SCHEMBL27735529 | 0.82 | PARP1 (0.38) | PARP1GAAMAPT | |
| Acetone SCHEMBL28779633 | 0.82 | SMN1; SMN2 (0.37) | PARP1GAAMAPT | |
| SCHEMBL11072820 | 0.78 | KEAP1 (0.35) | PARP1MAPT | |
| Maleic Acid SCHEMBL29935550 | 0.77 | HCAR2 (0.43) | MAPT | |
| Fumaric Acid SCHEMBL5330585 | 0.77 | HCAR2 (0.43) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611449-A1 | ADMINISTRATION OF LORCASERIN TO INDIVIDUALS WITH RENAL IMPAIRMENT | Arena Pharmaceuticals, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012030939-A1 | ADMINISTRATION OF LORCASERIN TO INDIVIDUALS WITH RENAL IMPAIRMENT | ARENA PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| EP-0103961-B1 | ALLYLOXY- AND ALLYLTHIO-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINES | SMITHKLINE BECKMAN CORPORATION (US) | 1986-04-02 | — | — | EP | disclosed |
| EP-0044709-B1 | NEW DOPAMINERGIC BENZAZEPINES | SMITHKLINE BECKMAN CORPORATION (US) | 1984-03-14 | — | — | EP | disclosed |
| EP-0022330-B1 | SYNERGISTIC ANTIHYPERTENSIVE COMPOSITIONS | SMITHKLINE BECKMAN CORPORATION (US) | 1983-12-21 | — | — | EP | disclosed |
| EP-0004794-B1 | SUBSTITUTED BENZAZEPINES, PROCESSES FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITHKLINE BECKMAN CORPORATION (US) | 1982-04-28 | — | — | EP | disclosed |